1. Home
  2. NUVL vs MUSA Comparison

NUVL vs MUSA Comparison

Compare NUVL & MUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Murphy USA Inc.

MUSA

Murphy USA Inc.

HOLD

Current Price

$405.15

Market Cap

7.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
MUSA
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail-Auto Dealers and Gas Stations
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.2B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
MUSA
Price
$104.39
$405.15
Analyst Decision
Strong Buy
Buy
Analyst Count
14
7
Target Price
$134.29
$476.50
AVG Volume (30 Days)
828.0K
239.0K
Earning Date
10-30-2025
02-04-2026
Dividend Yield
N/A
0.62%
EPS Growth
N/A
N/A
EPS
N/A
23.64
Revenue
N/A
$17,008,099,999.00
Revenue This Year
N/A
$11.09
Revenue Next Year
N/A
$3.18
P/E Ratio
N/A
$17.19
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$345.23
52 Week High
$112.88
$556.87

Technical Indicators

Market Signals
Indicator
NUVL
MUSA
Relative Strength Index (RSI) 51.87 65.02
Support Level $103.52 $381.58
Resistance Level $107.99 $402.33
Average True Range (ATR) 3.18 11.51
MACD -0.93 2.01
Stochastic Oscillator 10.43 81.72

Price Performance

Historical Comparison
NUVL
MUSA

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About MUSA Murphy USA Inc.

Murphy USA operates more than 1,700 fueling stations and convenience stores primarily across the Midwest and Southeastern United States. The firm owns about 75% of its locations, with most stores situated in high-traffic areas near Walmart supercenters. Murphy's stores typically range from 1,400-2,800 square feet, with most of its in-store sales derived from tobacco and nicotine products. The company acquired about 150 QuickChek stores in 2021, boosting its presence in grocery and foodservice. Murphy generates about two thirds of its profit from fuel retailing, with the remaining third coming from in-store sales.

Share on Social Networks: